Patents by Inventor Kwong Wah Lai

Kwong Wah Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10457654
    Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 29, 2019
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Daniel Sutherlin, Steven McKerrall, Michael Scott Wilson, Kwong Wah Lai, Philippe Bergeron, Birong Zhang, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Liang Zhao, Claudio Sturino
  • Publication number: 20190300544
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 3, 2019
    Applicant: GENENTECH, INC.
    Inventors: Steven MCKERRALL, Brian Salvatore SAFINA, Aleksandr KOLESNIKOV, Birong ZHANG, Wenfeng LIU, Kwong Wah LAI
  • Publication number: 20190263786
    Abstract: The invention provides a compound as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 29, 2019
    Applicant: GENENTECH, INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Kwong Wah LAI, Zhiguo LIU, Wenfeng LIU, Ramsay BEVERIDGE, Jean-Philippe LECLERC, Alexandre LEMIRE, Liang ZHAO, Claudio STURINO
  • Publication number: 20190241558
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 21, 2018
    Publication date: August 8, 2019
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Publication number: 20190152949
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 21, 2018
    Publication date: May 23, 2019
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Patent number: 10206931
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: February 19, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: F. Anthony Romero, Steven R. Magnuson, Richard Pastor, Vickie Hsiao-Wei Tsui, Jeremy Murray, Terry Crawford, Daniel J. Burdick, Brian K. Albrecht, Alexandre Cote, Alexander M. Taylor, Christopher G. Nasveschuck, Yves LeBlanc, Michael Charles Hewitt, Kwong Wah Lai, Kevin Chen
  • Publication number: 20180291014
    Abstract: The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: March 28, 2018
    Publication date: October 11, 2018
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Phillipe BERGERON, Kristen BURFORD, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Abid HASAN, Kwong Wah LAI, Zhiguo LIU, Steven MCKERRALL, Teresa Phuongtram NGUYEN, Brian SAFINA, Daniel SUTHERLIN, Tao WANG
  • Patent number: 10035801
    Abstract: Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 31, 2018
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Victor S. Gehling, Jean-Christophe Harmange, Kwong Wah Lai, Jun Liang, Peter Dragovich, Daniel F. Ortwine, Sharada Labadie, Birong Zhang, James Richard Kiefer
  • Patent number: 10022354
    Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 17, 2018
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS INC.
    Inventors: Kwong Wah Lai, Jun Liang, Birong Zhang, Sharada Labadie, Daniel Ortwine, Peter Dragovich, James Kiefer, Victor S. Gehling, Jean-Christophe Harmange
  • Publication number: 20180105504
    Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1-Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: October 31, 2017
    Publication date: April 19, 2018
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Michael Scott WILSON, Kwong Wah LAI, Philippe BERGERON, Birong ZHANG
  • Publication number: 20170333406
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 23, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Publication number: 20170312252
    Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: April 7, 2017
    Publication date: November 2, 2017
    Inventors: Kwong Wah Lai, Jun Liang, Birong Zhang, Sharada Labadie, Daniel Ortwine, Peter Dragovich, James Kiefer, Victor S. Gehling, Jean-Christophe Harmange
  • Publication number: 20170312292
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: April 7, 2017
    Publication date: November 2, 2017
    Inventors: Anthony F. Romero, Steven R. Magnuson, Richard Pastor, Vickie Hsiao-Wei Tsui, Jeremy Murray, Terry Crawford, Daniel J. Burdick, Brian K. Albrecht, Alexandre Cote, Alexander M. Taylor, Christopher G. Nasveschuck, Yves LeBlanc, Michael Charles Hewitt, Kwong Wah Lai, Kevin Chen
  • Patent number: 9763922
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 19, 2017
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Publication number: 20170001990
    Abstract: The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 15, 2016
    Publication date: January 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Jinhua CHEN, Charles Z. DING, Peter DRAGOVICH, Benjamin FAUBER, Zhenting GAO, Sharada S. LABADIE, Kwong Wah LAI, Hans Edward PURKEY, Kirk ROBARGE, Binqing WEI, Aihe ZHOU
  • Publication number: 20160158207
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 9, 2016
    Applicants: Genentech, Inc., Constellation Pharmaceuticals, Inc.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Publication number: 20160060267
    Abstract: Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.
    Type: Application
    Filed: March 13, 2014
    Publication date: March 3, 2016
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Victor S. Gehling, Jean-Christophe Harmange, Kwong Wah Lai, Jun Liang, Peter Dragovich, Dan Ortwine, Sharada Labadie, Birong Zhang, Jim Kiefer